The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High Dose Chemotherapy (HDC) with Busulfan (Bu) and Melphalan (Mel) in the Treatment of Multiple Myeloma. An Intent to Treat Analysis.
 
Kim Anna Reiss
No Relationships to Disclose
 
Kara Noelle Maxwell
No Relationships to Disclose
 
Katharine Nathanson
No Relationships to Disclose
 
Ursina R. Teitelbaum
No Relationships to Disclose
 
Mark H. O'Hara
No Relationships to Disclose
 
Peter J. O'Dwyer
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Forty Seven; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics
 
Charles Schneider
No Relationships to Disclose
 
Erica L. Carpenter
Research Funding - Janssen; Merck
Travel, Accommodations, Expenses - Silicon Biosytems
 
Rosemarie Mick
Stock and Other Ownership Interests - Editas Medicine
Consulting or Advisory Role - Infiniti Medical
 
Susan M. Domchek
Honoraria - AstraZeneca; Clovis Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Pharmamar (Inst)